WO2024162930A1 - Film coating tablets of empagliflozin and metformin hydrochloride - Google Patents

Film coating tablets of empagliflozin and metformin hydrochloride Download PDF

Info

Publication number
WO2024162930A1
WO2024162930A1 PCT/TR2024/050059 TR2024050059W WO2024162930A1 WO 2024162930 A1 WO2024162930 A1 WO 2024162930A1 TR 2024050059 W TR2024050059 W TR 2024050059W WO 2024162930 A1 WO2024162930 A1 WO 2024162930A1
Authority
WO
WIPO (PCT)
Prior art keywords
film coated
coated tablet
tablet according
starch
empagliflozin
Prior art date
Application number
PCT/TR2024/050059
Other languages
French (fr)
Inventor
Fatih Sunel
Nur PEHLIVAN AKALIN
Furkan KIVANC
Tolga GULER
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2023/001202 external-priority patent/TR2023001202A1/en
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2024162930A1 publication Critical patent/WO2024162930A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient

Definitions

  • the present invention relates to a film coated tablet comprising empagliflozin and metformin hydrochloride wherein comprising at least one disintegrant which is croscarmellose sodium, sodium starch glycollate, sodium alginate, starch, magnesium aluminum silicate or a mixture thereof.
  • the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged.
  • Type 1 diabetes the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
  • Type 2 diabetes the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweighed.
  • Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
  • Metformin is antidiabetics having an orally-administrated biguanide structure.
  • Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform.
  • Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha-glucosidase inhibitors, or insulin.
  • metformin hydrochloride is 1,1-dimethylbiguanide hydrochloride, has the following chemical structure of Formula I.
  • Empagliflozin is a known SGLT2 inhibitor that is described for the treatment or improvement in glycemic control in patients with type 2 diabetes mellitus.
  • the chemical name of empagliflozin is 1 - chloro-4-(3-D-glucopyranos-l -yl)- 2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene and its chemical structure is shown in the Formula II.
  • Combination product of empagliflozin and metformin hydrochloride is marketed under the trademark Synjardy®.
  • the combination is to help control blood glucose in people with T2D.
  • Empagliflozin a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney.
  • SGLT2 sodium glucose co-transporter-2
  • Active ingredients have some disadvantages in the formulation and process.
  • the main problem encountered when preparing formulations comprising empagliflozin is low solubility, leading to difficulties with disintegration and dissolution times.
  • metformin is a very poorly compressible active substance and metformin presents in high amounts in a composition. This causes some problems for examples; compressibility, homogeneity, flowability and dissolution profile.
  • WO2011039337 (Al) application discloses pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
  • CN104586834 (A) application discloses a pharmaceutical composition of empagliflozin and metformin, a preparation method and application thereof.
  • the composition comprises the following components: i.) empagliflozin; ii.) metformin hydrochloride; and one or more fillers; one or more adhesives; one or more flow aids and one or more lubricants.
  • the main object of the present invention is to provide a film coated tablet comprising empagliflozin and metformin hydrochloride with having the desired level of dissolution rate and excellent physicochemical properties, such as flowability, compressibility, homogeneity, and content uniformity which overcomes the above-described problems in the prior art and have additive advantages over them.
  • Another object of the present invention is to provide a film coated tablet comprising empagliflozin and metformin hydrochloride with having high stability.
  • Another object of the present invention is to provide a process for preparing a film coated tablet comprising empagliflozin and metformin hydrochloride.
  • the process is a simple, rapid, cost effective, time-saving, and industrially convenient method.
  • a film coated tablet comprises metformin hydrochloride and empagliflozin wherein comprising at least one disintegrant which is croscarmellose sodium, crospovidone, sodium starch glycollate, sodium alginate, starch, magnesium aluminum silicate or a mixture thereof.
  • the film coated tablet is obtained which provides the desired dissolution profile. Also, it has been surprisingly found that the selected disintegrant provides good compressibility of the tablet. This choice of disintegrant eliminates the disadvantages of both active agents and provides an effective tablet formulation.
  • the disintegrant is croscarmellose sodium.
  • the amount of disintegrant is 1.0% to 15.0% by weight in the total composition.
  • the amount of disintegrant is 2.0% to 7.0% by weight in the total composition.
  • a film coated tablet comprises 70.0% to 90.0% of metformin hydrochloride and 0.1% to 5.0% of empagliflozin by weight in the total composition.
  • the film coated tablet further comprises at least one diluent, at least one binder and at least one glidant/lubricant.
  • Suitable diluents are selected from the group comprising lactose monohydrate, corn starch, microcrystalline cellulose, lactose, anhydrous lactose, starch, mannitol, calcium hydrogen phosphate dihydrate, dicalcium hydrogen phosphate anhydrate, calcium phosphate trihydrate, neutral pellets, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides or mixtures thereof.
  • the diluent is lactose monohydrate.
  • the filler provides flowability and homogeneity of the powder mixture.
  • the amount of diluents is 1.0% to 15.0% by weight in the total composition.
  • the amount of diluents is 1.0% to 7.0% by weight in the total composition.
  • Suitable binders are selected from the group comprising hydroxypropyl cellulose, hydroxypropyl methylcellulose, pregelatinized starch, polyvinylpyrrolidone, carboxymethylcellulose sodium, cellulose acetate phthalate, chitosan, dextrose, ethylcellulose, glyceryl behenate, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl starch, magnesium aluminum silicate, polyethylene oxide, polymethacrylates, polyoxyethilene-alkyl ethers or mixtures thereof.
  • the amount of binders is 2.0% to 15.0% by weight in the total composition.
  • the amount of binders is 2.0% to 10.0% by weight in the total composition.
  • the binder is hydroxypropyl cellulose.
  • hydroxypropyl cellulose LF is hydroxypropyl cellulose LF.
  • Suitable glidants/lubricants are selected from the group comprising anhydrous colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, magnesium oxide, starch, silicone dioxide, talc, polyethylene glycol, stearic acid, aluminum silicate, magnesium silicate, colloidal silica or mixtures thereof.
  • the glidant/lubricant is anhydrous colloidal silicon dioxide or magnesium stearate or mixtures thereof. These excipients provide the flowability of the powder mixture.
  • the amount of glidants/lubricants is 0.2% to 4.0% by weight in the total composition.
  • the amount of glidants/lubricants is 0.5% to 2.5% by weight in the total composition.
  • the film coated tablet is coated with at least one film coating agent.
  • HPMC-based coating is used.
  • Suitable film coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, talc, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), glycerin, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), iron oxide yellow, iron oxides, all kinds of Opadry®, pigments, dyes, titanium dioxide, coloring agent or mixtures thereof.
  • the film coated tablet comprises; a) Metformin HCI b) Empagliflozin c) Croscarmellose sodium d) Lactose monohydrate e) Hydroxypropyl Cellulose.
  • the film coated tablet comprises; a) Metformin HCI b) Empagliflozin c) Croscarmellose sodium d) Lactose monohydrate e) Hydroxypropyl Cellulose LF f) Anhydrous colloidal silicon dioxide g) Magnesium stearate
  • the film coated tablet of the present invention is prepared wet granulation.
  • a process for the preparation of the film coated tablet comprises the following steps: a) Sieving metformin HCI, b) Mixing Metformin HCI, empagliflozin, lactose monohydrate and hydroxypropyl Cellulose, c) Granulating the mixture with pure water, d) Drying the wet granules and sieving, e) Sieving anhydrous colloidal silicon dioxide, f) Adding anhydrous colloidal silicon dioxide, magnesium stearate and croscarmellose sodium and then adding the mixture at step (d) and mixing, g) Compressing the mixture into the tablet, h) Coating the tablets with film coating agent.
  • a solvent is used at wet granulation.
  • Suitable solvents are selected from the group comprising pure water, dichloromethane, 0.1N HCI, methanol, ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, cyclomethicone or mixtures thereof.
  • the solvent is water.
  • Example 1 The tablet formulation
  • Example 2 The tablet formulation
  • a solvent for example; pure water

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a film coated tablet comprising empagliflozin and metformin hydrochloride wherein comprising at least one disintegrant which is croscarmellose sodium, sodium starch glycollate, sodium alginate, starch, magnesium aluminum silicate or a mixture thereof. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.

Description

FILM COATING TABLETS OF EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
Field of the Invention
The present invention relates to a film coated tablet comprising empagliflozin and metformin hydrochloride wherein comprising at least one disintegrant which is croscarmellose sodium, sodium starch glycollate, sodium alginate, starch, magnesium aluminum silicate or a mixture thereof. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.
Background of the Invention
Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors. There are two main types of diabetes; Type 1 and Type 2: Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose. In Type 2 diabetes, the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweighed. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
Metformin is antidiabetics having an orally-administrated biguanide structure. Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform. Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha-glucosidase inhibitors, or insulin.
The chemical name of metformin hydrochloride is 1,1-dimethylbiguanide hydrochloride, has the following chemical structure of Formula I.
Figure imgf000002_0001
Formula I Empagliflozin is a known SGLT2 inhibitor that is described for the treatment or improvement in glycemic control in patients with type 2 diabetes mellitus. The chemical name of empagliflozin is 1 - chloro-4-(3-D-glucopyranos-l -yl)- 2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene and its chemical structure is shown in the Formula II.
Figure imgf000003_0001
Formula II
Combination product of empagliflozin and metformin hydrochloride is marketed under the trademark Synjardy®. The combination is to help control blood glucose in people with T2D. Empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney.
Active ingredients have some disadvantages in the formulation and process. The main problem encountered when preparing formulations comprising empagliflozin is low solubility, leading to difficulties with disintegration and dissolution times. Furthermore, metformin is a very poorly compressible active substance and metformin presents in high amounts in a composition. This causes some problems for examples; compressibility, homogeneity, flowability and dissolution profile.
WO2011039337 (Al) application discloses pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
CN104586834 (A) application discloses a pharmaceutical composition of empagliflozin and metformin, a preparation method and application thereof. The composition comprises the following components: i.) empagliflozin; ii.) metformin hydrochloride; and one or more fillers; one or more adhesives; one or more flow aids and one or more lubricants.
In the prior art, there are also several patents which disclose empagliflozin and metformin hydrochloride in oral pharmaceutical dosage forms. However, because of the dissolution problem of empagliflozin, and the poorly compressible of metformin, an effective formulation and method has not been disclosed.
There still remains a need in the art to provide an improved a film coated tablet comprising empagliflozin and metformin hydrochloride having high solubility, excellent pharmacotechnical properties and accordingly a high bioavailability and a long-term stability which is also obtained by using an effective process.
Detailed Description of the Invention
The main object of the present invention is to provide a film coated tablet comprising empagliflozin and metformin hydrochloride with having the desired level of dissolution rate and excellent physicochemical properties, such as flowability, compressibility, homogeneity, and content uniformity which overcomes the above-described problems in the prior art and have additive advantages over them.
Another object of the present invention is to provide a film coated tablet comprising empagliflozin and metformin hydrochloride with having high stability.
Another object of the present invention is to provide a process for preparing a film coated tablet comprising empagliflozin and metformin hydrochloride. The process is a simple, rapid, cost effective, time-saving, and industrially convenient method.
The main problem encountered when preparing formulations comprising empagliflozin is low solubility, leading to difficulties with disintegration and dissolution times. Furthermore, metformin is a very poorly compressible active substance and metformin presents in high amounts in a composition. This causes some problems for examples; compressibility, homogeneity, flowability and dissolution profile. Therefore, the excipients and process steps used are very important. We found that the selected disintegrant excipient eliminated the described above problems.
According to an embodiment of the present invention, a film coated tablet comprises metformin hydrochloride and empagliflozin wherein comprising at least one disintegrant which is croscarmellose sodium, crospovidone, sodium starch glycollate, sodium alginate, starch, magnesium aluminum silicate or a mixture thereof. The film coated tablet is obtained which provides the desired dissolution profile. Also, it has been surprisingly found that the selected disintegrant provides good compressibility of the tablet. This choice of disintegrant eliminates the disadvantages of both active agents and provides an effective tablet formulation.
According to an embodiment of the present invention, preferably, the disintegrant is croscarmellose sodium. According to an embodiment of the present invention, the amount of disintegrant is 1.0% to 15.0% by weight in the total composition. Preferably, the amount of disintegrant is 2.0% to 7.0% by weight in the total composition.
According to an embodiment of the present invention, a film coated tablet comprises 70.0% to 90.0% of metformin hydrochloride and 0.1% to 5.0% of empagliflozin by weight in the total composition.
According to an embodiment of the present invention, the film coated tablet further comprises at least one diluent, at least one binder and at least one glidant/lubricant.
Encountered while developing formulations is the flowability-problem and homogeneity of metformin HCI, which makes the production difficult. It has been observed that this problem is overcome by using at least one diluent.
Suitable diluents are selected from the group comprising lactose monohydrate, corn starch, microcrystalline cellulose, lactose, anhydrous lactose, starch, mannitol, calcium hydrogen phosphate dihydrate, dicalcium hydrogen phosphate anhydrate, calcium phosphate trihydrate, neutral pellets, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides or mixtures thereof.
According to an embodiment of the present invention, the diluent is lactose monohydrate. The filler provides flowability and homogeneity of the powder mixture.
According to an embodiment of the present invention, the amount of diluents is 1.0% to 15.0% by weight in the total composition. Preferably, the amount of diluents is 1.0% to 7.0% by weight in the total composition.
Suitable binders are selected from the group comprising hydroxypropyl cellulose, hydroxypropyl methylcellulose, pregelatinized starch, polyvinylpyrrolidone, carboxymethylcellulose sodium, cellulose acetate phthalate, chitosan, dextrose, ethylcellulose, glyceryl behenate, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl starch, magnesium aluminum silicate, polyethylene oxide, polymethacrylates, polyoxyethilene-alkyl ethers or mixtures thereof.
According to an embodiment of the present invention, the amount of binders is 2.0% to 15.0% by weight in the total composition. Preferably, the amount of binders is 2.0% to 10.0% by weight in the total composition. According to an embodiment of the present invention, the binder is hydroxypropyl cellulose.
Especially, it is hydroxypropyl cellulose LF.
Suitable glidants/lubricants are selected from the group comprising anhydrous colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, magnesium oxide, starch, silicone dioxide, talc, polyethylene glycol, stearic acid, aluminum silicate, magnesium silicate, colloidal silica or mixtures thereof.
According to an embodiment of the present invention, the glidant/lubricant is anhydrous colloidal silicon dioxide or magnesium stearate or mixtures thereof. These excipients provide the flowability of the powder mixture.
According to an embodiment of the present invention, the amount of glidants/lubricants is 0.2% to 4.0% by weight in the total composition. Preferably, the amount of glidants/lubricants is 0.5% to 2.5% by weight in the total composition.
According to an embodiment of the present invention, the film coated tablet is coated with at least one film coating agent. Especially, HPMC-based coating is used.
Suitable film coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, talc, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), glycerin, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), iron oxide yellow, iron oxides, all kinds of Opadry®, pigments, dyes, titanium dioxide, coloring agent or mixtures thereof.
According to an embodiment of the present invention, the film coated tablet comprises; a) Metformin HCI b) Empagliflozin c) Croscarmellose sodium d) Lactose monohydrate e) Hydroxypropyl Cellulose.
According to an embodiment of the present invention, the film coated tablet comprises; a) Metformin HCI b) Empagliflozin c) Croscarmellose sodium d) Lactose monohydrate e) Hydroxypropyl Cellulose LF f) Anhydrous colloidal silicon dioxide g) Magnesium stearate
The film coated tablet of the present invention is prepared wet granulation.
According to one embodiment of the present invention, a process for the preparation of the film coated tablet comprises the following steps: a) Sieving metformin HCI, b) Mixing Metformin HCI, empagliflozin, lactose monohydrate and hydroxypropyl Cellulose, c) Granulating the mixture with pure water, d) Drying the wet granules and sieving, e) Sieving anhydrous colloidal silicon dioxide, f) Adding anhydrous colloidal silicon dioxide, magnesium stearate and croscarmellose sodium and then adding the mixture at step (d) and mixing, g) Compressing the mixture into the tablet, h) Coating the tablets with film coating agent.
According to this embodiment of the present invention, a solvent is used at wet granulation.
Suitable solvents are selected from the group comprising pure water, dichloromethane, 0.1N HCI, methanol, ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, cyclomethicone or mixtures thereof. Preferably, the solvent is water.
Example 1: The tablet formulation
Figure imgf000007_0001
Example 2: The tablet formulation
Figure imgf000008_0001
A process for example 1 or 2; a) Sieving metformin HCI through 2 mm, b) Mixing Metformin HCI, empagliflozin, lactose monohydrate and hydroxypropyl Cellulose c) Granulating the mixture with a solvent (for example; pure water) d) Drying the wet granules at Fluid Bed Dryer and sieving through 1.0 mm, e) Sieving anhydrous colloidal silicon dioxide through 0.85, f) Adding anhydrous colloidal silicon dioxide, magnesium stearate and croscarmellose sodium and then adding the mixture at step (d) and mixing, g) Compressing the mixture into the tablet, h) Coating the tablets with film coating agent.

Claims

1) A film coated tablet comprises metformin hydrochloride and empagliflozin wherein comprising at least one disintegrant which is croscarmellose sodium, sodium starch glycolate, crospovidone, sodium alginate, starch, magnesium aluminum silicate or a mixture thereof.
2) The film coated tablet according to claim 1, wherein the disintegrant is croscarmellose sodium.
3) The film coated tablet according to claim 1, wherein the amount of disintegrant is 1.0% to 15.0% by weight in the total composition.
4) The film coated tablet according to claim 1, wherein comprises 70.0% to 90.0% of metformin hydrochloride and 0.1% to 5.0% of empagliflozin by weight in the total composition.
5) The film coated tablet according to claim 1, wherein further comprises at least one diluent, at least one binder and at least one glidant/lubricant.
6) The film coated tablet according to claim 5, wherein diluents are selected from the group comprising lactose monohydrate, corn starch, microcrystalline cellulose, lactose, anhydrous lactose, starch, mannitol, calcium hydrogen phosphate dihydrate, dicalcium hydrogen phosphate anhydrate, calcium phosphate trihydrate, neutral pellets, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides or mixtures thereof.
7) The film coated tablet according to claim 6, wherein the diluent is lactose monohydrate.
8) The film coated tablet according to claim 6 or 7, wherein the amount of diluents is 1.0% to 15.0% by weight in the total composition.
9) The film coated tablet according to claim 5, wherein binders are selected from the group comprising hydroxypropyl cellulose, hydroxypropyl methylcellulose, pregelatinized starch, polyvinylpyrrolidone, carboxymethylcellulose sodium, cellulose acetate phthalate, chitosan, dextrose, ethylcellulose, glyceryl behenate, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl starch, magnesium aluminum silicate, polyethylene oxide, polymethacrylates, polyoxyethilene-alkyl ethers or mixtures thereof.
10) The film coated tablet according to claim 9, wherein the amount of binders is 2.0% to 15.0% by weight in the total composition. 11) The film coated tablet according to claim 9, wherein the binder is hydroxypropyl cellulose. Especially, it is hydroxypropyl cellulose LF.
12) The film coated tablet according to claim 5, wherein glidants/lubricants are selected from the group comprising anhydrous colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, magnesium oxide, starch, silicone dioxide, talc, polyethylene glycol, stearic acid, aluminum silicate, magnesium silicate, colloidal silica or mixtures thereof.
13) The film coated tablet according to claim 12, wherein the glidant/lubricant is anhydrous colloidal silicon dioxide or magnesium stearate or mixtures thereof.
14) The film coated tablet according to claim 5, wherein comprises; a) Metformin HCI b) Empagliflozin c) Croscarmellose sodium d) Lactose monohydrate e) Hydroxypropyl Cellulose.
PCT/TR2024/050059 2023-02-02 2024-01-25 Film coating tablets of empagliflozin and metformin hydrochloride WO2024162930A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2023001202 2023-02-02
TR2023/001202 TR2023001202A1 (en) 2023-02-02 FILM-COATED EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE TABLETS

Publications (1)

Publication Number Publication Date
WO2024162930A1 true WO2024162930A1 (en) 2024-08-08

Family

ID=92147199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2024/050059 WO2024162930A1 (en) 2023-02-02 2024-01-25 Film coating tablets of empagliflozin and metformin hydrochloride

Country Status (1)

Country Link
WO (1) WO2024162930A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200306246A1 (en) * 2019-03-25 2020-10-01 The George Institute for Global Health Low-dose triple combination formulation
CN115154456A (en) * 2022-05-24 2022-10-11 通化东宝药业股份有限公司 Pharmaceutical composition of metformin and engelizin and preparation method thereof
KR20230001000A (en) * 2021-06-25 2023-01-03 (주)휴온스 Empagliflozin and Metformin Combination Formulation with Improved Drug-Release Properties

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200306246A1 (en) * 2019-03-25 2020-10-01 The George Institute for Global Health Low-dose triple combination formulation
KR20230001000A (en) * 2021-06-25 2023-01-03 (주)휴온스 Empagliflozin and Metformin Combination Formulation with Improved Drug-Release Properties
CN115154456A (en) * 2022-05-24 2022-10-11 通化东宝药业股份有限公司 Pharmaceutical composition of metformin and engelizin and preparation method thereof

Similar Documents

Publication Publication Date Title
EP4051246A1 (en) Bilayer tablet formulations comprising dapagliflozin and metformin
WO2020242413A1 (en) A combination comprising alogliptin and metformin
EP4285893A1 (en) A combination comprising empagliflozin and metformin hydrochloride
EP4285894A1 (en) A formulation of empagliflozin and metformin hydrochloride
US20190110994A1 (en) Pharmaceutical composition of dapagliflozin
WO2023234899A1 (en) A bilayer tablet formulation comprising empagliflozin and metformin
EP2638898A1 (en) Metformin and Pioglitazone Formulation with Different Release Profiles
WO2024162930A1 (en) Film coating tablets of empagliflozin and metformin hydrochloride
EP4410280A1 (en) Film coating tablets of empagliflozin and metformin hydrochloride
WO2022119541A1 (en) A film coated tablet formulation comprising dapagliflozin and metformin hydrochloride
WO2023234900A1 (en) A tablet comprising empagliflozin and metformin hydrochloride
WO2023234901A1 (en) A formulation comprising empagliflozin and metformin hydrochloride
EP2181705A1 (en) Sustained-release formulation of gliclazide
TR2023001202A1 (en) FILM-COATED EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE TABLETS
TR2022008871A2 (en) A COMBINATION CONTAINING EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
EP4161525A1 (en) The process for the preparation of a film coated tablet comprising linagliptin and metformin
TR2022009903A2 (en) A FORMULATION OF EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
TR2022008869A1 (en) A TABLET CONTAINING EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
EP4212150A1 (en) A bilayer tablet composition comprising amorphous dapagliflozin and metformin
WO2022119540A2 (en) A process for formulations of dapagliflozin and metformin hydrochloride
EP4079296A1 (en) A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
TR2022008870A1 (en) A DOUBLE-LAYER TABLET FORMULATION CONTAINING EMPAGLIFLOZIN AND METFORMIN
EP3342402A1 (en) Pharmaceutical compositions of metformin hydrochloride and pioglitazone hydrochloride
EP4008318A1 (en) A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
TR2022008868A1 (en) A FORMULATION CONTAINING EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24750659

Country of ref document: EP

Kind code of ref document: A1